Your browser is no longer supported. Please, upgrade your browser.
Settings
ARWR Arrowhead Pharmaceuticals, Inc. daily Stock Chart
ARWR [NASD]
Arrowhead Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own4.00% Shs Outstand87.63M Perf Week1.52%
Market Cap1.46B Forward P/E- EPS next Y-0.60 Insider Trans-10.81% Shs Float80.15M Perf Month21.41%
Income-44.30M PEG- EPS next Q-0.19 Inst Own49.00% Short Float14.38% Perf Quarter137.80%
Sales22.20M P/S65.80 EPS this Y65.20% Inst Trans5.89% Short Ratio6.30 Perf Half Y191.43%
Book/sh1.36 P/B12.26 EPS next Y18.90% ROA-40.80% Target Price13.50 Perf Year989.54%
Cash/sh1.04 P/C15.96 EPS next 5Y7.33% ROE-49.70% 52W Range1.48 - 16.76 Perf YTD352.99%
Dividend- P/FCF- EPS past 5Y24.50% ROI-44.10% 52W High-0.54% Beta1.90
Dividend %- Quick Ratio10.20 Sales past 5Y192.40% Gross Margin- 52W Low1026.35% ATR0.86
Employees93 Current Ratio10.20 Sales Q/Q-92.20% Oper. Margin- RSI (14)73.42 Volatility5.05% 5.90%
OptionableYes Debt/Eq0.02 EPS Q/Q-118.60% Profit Margin- Rel Volume1.23 Prev Close16.45
ShortableYes LT Debt/Eq0.02 EarningsAug 07 AMC Payout- Avg Volume1.83M Price16.67
Recom1.80 SMA2012.95% SMA5038.45% SMA200140.32% Volume2,255,939 Change1.34%
Jul-02-18Reiterated Chardan Capital Markets Buy $9.50 → $16
May-09-18Upgrade Cantor Fitzgerald Neutral → Overweight $13
Mar-27-18Initiated Jefferies Buy $10
Feb-12-18Reiterated Cantor Fitzgerald Neutral $2 → $5
Feb-12-18Reiterated B. Riley FBR, Inc. Neutral $3 → $4
Jan-05-18Initiated B. Riley FBR, Inc. Neutral $3
Nov-27-17Upgrade Piper Jaffray Neutral → Overweight
Sep-18-17Upgrade William Blair Mkt Perform → Outperform
Nov-30-16Downgrade William Blair Outperform → Mkt Perform
Nov-30-16Downgrade Piper Jaffray Overweight → Neutral
Nov-30-16Downgrade Chardan Capital Markets Buy → Neutral $8 → $2
Nov-30-16Downgrade Cantor Fitzgerald Buy → Hold
Nov-10-16Reiterated Chardan Capital Markets Buy $10 → $8
Aug-18-16Initiated Cantor Fitzgerald Buy $15
May-19-16Initiated Chardan Capital Markets Buy $12
Sep-25-15Reiterated Piper Jaffray Overweight $12 → $20
Oct-09-14Downgrade RBC Capital Mkts Outperform → Sector Perform $35 → $9
Mar-05-14Initiated RBC Capital Mkts Outperform $35
Mar-05-14Initiated Deutsche Bank Buy $45
Feb-26-13Initiated Dawson James Buy $4
Jul-14-18 07:16AM  The 4 Best Biotech Stocks of 2018 (So Far) Motley Fool
Jul-13-18 08:00AM  Upcoming Catalysts Could Send This Unknown Stock Up 300% or More ACCESSWIRE
Jul-12-18 07:15AM  Free Pre-Market Technical Recap on ArQule and Three Additional Biotech ACCESSWIRE
Jul-11-18 09:15AM  3 Huge Biotech Winners in 2018 (So Far) Motley Fool
Jul-02-18 03:06PM  4 Biotech Stocks That Tripled in the First Half of 2018 Motley Fool +9.34%
Jun-29-18 07:30AM  Arrowhead Presents New Clinical Data on ARO-AAT at Alpha-1 National Education Conference Business Wire +5.02%
Jun-28-18 06:33AM  The 3 Best Biotech Stocks of 2018 So Far Motley Fool
Jun-27-18 07:30AM  Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency Business Wire
Jun-26-18 08:30AM  Investor Expectations to Drive Momentum within AMC Entertainment, Arrowhead Pharmaceuticals, U.S. Silica, Catalent, RSP Permian, and KapStone Paper and Packaging Discovering Underlying Factors of Influence GlobeNewswire
Jun-21-18 08:07AM  3 Soaring Biotech Stocks. Can They Keep Climbing? Motley Fool
Jun-20-18 08:05AM  Arrowhead Pharmaceuticals Incs (NASDAQ:ARWR) Path To Profitability Simply Wall St. -6.35%
Jun-19-18 08:08AM  Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares Benzinga
08:00AM  Todays Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and ZIOPHARM Oncology ACCESSWIRE
Jun-18-18 03:11PM  Why Arrowhead Pharmaceuticals Stock Is Skyrocketing 23.3% Today Motley Fool +24.03%
07:30AM  Arrowhead Completes Enrollment in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Jun-13-18 07:05AM  Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities ACCESSWIRE
Jun-08-18 04:30PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
May-31-18 08:22AM  Benzinga's Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time Benzinga
May-30-18 07:30AM  Arrowhead Completes Enrollment in Single Dose Portion of Phase 1/2 Study of ARO-HBV Business Wire +5.73%
07:25AM  Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences Business Wire
May-21-18 08:00AM  Todays Research Reports on Stocks to Watch: Agile Therapeutics and Arrowhead Pharmaceuticals ACCESSWIRE
07:30AM  Arrowhead Pharmaceuticals Presents New Preclinical Data on ARO-ENaC for Treatment of Cystic Fibrosis Business Wire
May-15-18 11:52AM  Edited Transcript of ARWR earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
07:40AM  Wired News Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases ACCESSWIRE
May-14-18 07:30AM  Arrowhead Doses First Hepatitis B Patients in Multiple Dose Portion of Phase 1/2 Study of ARO-HBV Business Wire
May-12-18 07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
May-11-18 07:30AM  Arrowhead Pharmaceuticals Presents Preclinical Data on Expanding Cardiometabolic Pipeline Business Wire +8.33%
May-10-18 01:27PM  Four momentum stocks to watch amid earnings reports MarketWatch
09:44AM  Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results Benzinga
May-09-18 08:00AM  Recent Analysis Shows Extreme Networks, Lumber Liquidators, Owens-Illinois, Arrowhead Pharmaceuticals, Intrepid Potash, and General Cable Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire +16.13%
May-08-18 04:16PM  Arrowhead Research: Fiscal 2Q Earnings Snapshot Associated Press
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2018 Second Quarter Results Business Wire
May-01-18 07:30AM  Arrowhead Pharmaceuticals to Present Preclinical Data on Emerging Pipeline of RNAi Therapeutics Business Wire
Apr-24-18 04:01PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results Business Wire
Apr-11-18 07:00AM  Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress Business Wire +6.95%
Mar-28-18 07:30AM  Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress Business Wire
Mar-27-18 07:30AM  Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B Business Wire
Mar-20-18 04:05PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
Mar-12-18 07:30AM  Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Mar-07-18 08:30AM  Detailed Research: Economic Perspectives on Etsy, Tiffany, First BanCorp, Deere, Callaway Golf, and Arrowhead Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-06-18 07:30AM  Arrowhead to Present at Barclays Global Healthcare Conference 2018 Business Wire
Feb-27-18 08:30AM  Todays Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Zosano Pharma ACCESSWIRE
Feb-22-18 07:30AM  Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease Business Wire
Feb-15-18 01:32PM  Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT Business Wire +6.58%
07:30AM  Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B Business Wire
Feb-12-18 06:38PM  Edited Transcript of ARWR earnings conference call or presentation 9-Feb-18 9:30pm GMT Thomson Reuters StreetEvents -5.01%
Feb-09-18 04:09PM  Arrowhead Research reports 1Q loss Associated Press
04:00PM  Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results Business Wire
12:00PM  Arrowhead Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-07-18 08:28AM  [$$] OppenheimerFunds' Big Biotech Stock Buys Barrons.com
Feb-02-18 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results Business Wire
Jan-25-18 09:02AM  Taking Stock of Arrowhead Pharmaceuticals Financial Performance Market Realist
07:32AM  What Led to Arrowhead Pharmaceuticals Revenue Surge in 2017? Market Realist
Jan-24-18 01:30PM  Arrowheads Candidates for Hepatitis B, Cardiovascular Diseases Market Realist
12:00PM  Taking a Closer Look at Arrowhead Pharmaceuticals TRIM Platform Market Realist
10:25AM  Analysts Recommendations for Arrowhead and Its Peers Market Realist
Jan-22-18 04:00PM  Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million Business Wire
Jan-18-18 09:00AM  Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock Business Wire
Jan-17-18 04:01PM  Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock Business Wire
Jan-11-18 03:51PM  Here's Why Arrowhead Pharmaceuticals Inc. Is Up Today Motley Fool +14.55%
Dec-27-17 04:00PM  Arrowhead Pharmaceuticals Appoints William Waddill to Board of Directors Business Wire
Dec-26-17 08:43AM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q4, 2017 By the Numbers : December 26, 2017 Capital Cube
Dec-25-17 11:41AM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : December 25, 2017 Capital Cube
Dec-22-17 03:57PM  What Caused Arrowhead Pharmaceuticals to Skyrocket 10.5% Today Motley Fool +9.76%
07:30AM  Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV Business Wire
Dec-20-17 07:30AM  Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-AAT Business Wire +5.21%
Dec-18-17 06:27PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(C)(4) Business Wire
07:20AM  Blog Exposure - FDA Approves Aclaris Therapeutics' ESKATA Topical Solution for Treatment of Common Skin Growths ACCESSWIRE
Dec-14-17 11:29AM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: 2017 By the Numbers : December 14, 2017 Capital Cube -7.35%
Dec-13-17 07:38PM  Edited Transcript of ARWR earnings conference call or presentation 12-Dec-17 9:30pm GMT Thomson Reuters StreetEvents
07:00AM  3 Stocks to Watch on Wednesday: Arrowhead Pharmaceuticals Inc (ARWR), VeriFone Systems Inc (PAY) and Streamline Health Solutions Inc. (STRM) InvestorPlace
Dec-12-17 12:46PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : December 12, 2017 Capital Cube
Dec-06-17 04:00PM  ARWR: New HBV Clinical Data of ARC-520 Presented at HEP DART Meeting Zacks Small Cap Research
11:40AM  Arrowhead Pharma Wins in Midstage Hepatitis Study 24/7 Wall St.
07:00AM  Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy Business Wire
Dec-05-17 04:00PM  Arrowhead Pharmaceuticals to Webcast 2017 Fiscal Year End Results Business Wire
Nov-30-17 01:25PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : November 30, 2017 Capital Cube
08:20AM  Todays Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Array BioPharma Inc. ACCESSWIRE
Nov-14-17 07:30AM  Arrowhead to Present at 29th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-13-17 08:20AM  Analysis: Positioning to Benefit within Catabasis, Flowserve, MGIC Investment, Arrowhead, Silver Spring, and Live Nation Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-03-17 11:53AM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : November 3, 2017 Capital Cube
Oct-23-17 04:30PM  Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) Business Wire
08:00AM  Arrowhead Presents Promising Preclinical Data on Development of ARO-AAT for Treatment of Alpha-1 Liver Disease at Liver Meeting® 2017 Business Wire
Oct-16-17 09:48AM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 16, 2017 Capital Cube
Oct-10-17 09:30AM  Arrowhead Pharmaceuticals to Present Preclinical Data on ARO-AAT at The Liver Meeting® Business Wire -8.49%
Oct-03-17 04:00PM  Arrowhead to Present at Chardan Gene Therapy Conference Business Wire
Oct-02-17 10:40AM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : October 2, 2017 Capital Cube
Sep-27-17 02:00PM  Arrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment Business Wire +7.92%
Sep-15-17 12:06PM  Here's What Caused Arrowhead Pharmaceuticals' Stock to Spike Today Motley Fool +18.28%
08:00AM  Today's Research Reports on Trending Tickers: Aldeyra Therapeutics and Arrowhead Pharmaceuticals ACCESSWIRE
Sep-14-17 12:00PM  Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM Platform and Lead RNAi-based Drug Candidates Business Wire -20.96%
Sep-11-17 09:00PM  ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : September 12, 2017 Capital Cube +10.29%
04:00PM  Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-08-17 04:34PM  Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q3, 2017 By the Numbers : September 8, 2017 Capital Cube -6.04%
Sep-01-17 07:30AM  Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies Business Wire
Aug-13-17 08:31PM  Edited Transcript of ARWR earnings conference call or presentation 3-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-17 08:10AM  Todays Research Reports on Stocks to Watch: Horizon Pharma and Arrowhead Pharmaceuticals ACCESSWIRE -5.88%
Aug-03-17 04:00PM  Arrowhead Reports Fiscal 2017 Third Quarter Results Business Wire
11:50AM  Investor Network: Arrowhead Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Jul-27-17 04:00PM  Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results Business Wire
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myszkowski Kenneth AllenChief Financial OfficerJun 19Option Exercise2.0120,00040,200330,815Jun 20 09:18 PM
Myszkowski Kenneth AllenChief Financial OfficerJun 19Sale14.0120,000280,200310,815Jun 20 09:18 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 31Option Exercise2.0112,60025,326323,415Jun 01 05:34 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 31Sale11.0012,600138,600310,815Jun 01 05:34 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 30Option Exercise2.011,4002,814312,215Jun 01 05:34 PM
Myszkowski Kenneth AllenChief Financial OfficerMay 30Sale11.001,40015,400310,815Jun 01 05:34 PM
GIVEN DOUGLAS BDirectorApr 24Sale6.6325,000165,750155,000Apr 25 07:40 PM
Myszkowski Kenneth AllenChief Financial OfficerMar 27Option Exercise2.0120,00040,200330,815Mar 27 07:46 PM
Myszkowski Kenneth AllenChief Financial OfficerMar 27Sale8.0020,000160,000310,815Mar 27 07:46 PM
Anzalone Christopher RichardChief Executive OfficerMar 16Sale7.4026,000192,4001,968,789Mar 16 06:09 PM
Anzalone Christopher RichardChief Executive OfficerMar 15Sale7.41100,000741,0001,994,789Mar 15 06:58 PM
Anzalone Christopher RichardChief Executive OfficerMar 14Sale7.44100,000744,0002,094,789Mar 15 06:58 PM
Anzalone Christopher RichardChief Executive OfficerMar 13Sale7.43100,000743,0002,194,789Mar 15 06:58 PM
GIVEN BRUCE DChief Operating OfficerMar 05Sale6.7320,000134,600908,356Mar 05 08:48 PM
GIVEN BRUCE DChief Operating OfficerJan 01Sale3.6920,00073,800928,356Jan 03 07:25 PM